SCHEMBL1155857

SCHEMBL1155857

CCC(C)(C)P(C(C)(C)CC)C(C)(C)CC

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927939 0.75
SCHEMBL2928489 0.72 TSHR (0.40) TSHRTDP1ALDH1A1
SCHEMBL13294358 0.72 TSHR (0.40) TSHRTDP1ALDH1A1
SCHEMBL3836817 0.69 TSHR (0.38) TSHRTDP1
SCHEMBL2929567 0.69 TSHR (0.38) TSHRTDP1
SCHEMBL14244691 0.69 TSHR (0.38) TSHRTDP1
SCHEMBL2550050 0.69
SCHEMBL3835989 0.69 TSHR (0.38) TSHRTDP1
SCHEMBL2930618 0.69 TSHR (0.38) TSHRTDP1
Phosphine SCHEMBL23111707 0.67 TSHR (0.35) TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116693365-B Preparation method and preparation device system of hexafluorobutadiene 天津绿菱气体有限公司 2023-10-31 CN disclosed
CN-116693365-A Preparation method and preparation device system of hexafluorobutadiene 天津绿菱气体有限公司 2023-09-05 CN disclosed
EP-1534722-B1 RHODIUM AND IRIDIUM COMPLEXES MERCK PATENT GMBH (DE) 2017-03-22 EP disclosed
US-9556211-B2 Metal complex compound, hydrogen production catalyst and hydrogenation reaction catalyst each comprising the metal complex compound, and hydrogen production method and hydrogenation method each using the catalyst NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) 2017-01-31 US disclosed
US-20160264720-A1 METHOD FOR THE PRODUCTION OF POLYMERS MERCK PATENT GMBH (DE) 2016-09-15 US disclosed
US-9415370-B2 Method for the production of polymers MERCK PATENT GMBH (DE) 2016-08-16 US disclosed
EP-2552928-B1 A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST. CHROMAFORA AB (SE) 2015-04-15 EP disclosed
US-8735629-B2 Process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst CHROMAFORA AB (SE) 2014-05-27 US disclosed
EP-2289902-B1 Rhodium and iridium complexes MERCK PATENT GMBH (DE) 2014-04-30 EP disclosed
EP-2644611-A1 METAL COMPLEX COMPOUND, HYDROGEN PRODUCTION CATALYST AND HYDROGENATION REACTION CATALYST EACH COMPRISING THE METAL COMPLEX COMPOUND, AND HYDROGEN PRODUCTION METHOD AND HYDROGENATION METHOD EACH USING THE CATALYST National University Corporation Okayama University (JP) 2013-10-02 EP disclosed
EP-1379534-B1 RHODIUM AND IRIDIUM COMPLEXES COVION ORGANIC SEMICONDUCTORS (DE) 2004-12-15 EP disclosed
US-20040133004-A1 Rhodium and iridium complexes MERCK PATENT GMBH (DE) 2004-07-08 US disclosed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US disclosed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP disclosed
WO-2003084972-A1 RHODIUM COMPLEXES AND IRIDIUM COMPLEXES COVION ORGANIC SEMICONDUCTORS GMBH (DE) 2003-10-16 WO disclosed
US-20020165411-A1 Sterically hindered phosphine ligands and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-11-07 US disclosed
WO-2002048160-A1 STERICALLY HINDERED PHOSPHINE LIGANDS AND USES THEREOF YALE UNIVERSITY (US) 2002-06-20 WO disclosed
US-4721683-A LIQUID PHASE AMERICAN CYANAMID COMPANY (US) 1988-01-26 US disclosed
US-4595701-A Reacting carbon monoxide and hydrogen in liquid phase in the presence of a rhodium and trialkylphosphine catalyst AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1986-06-17 US disclosed
US-4504674-A METAL TREATED RUTHENIUM CATALYST E. I. DUPONT DE NEMOURS & CO. (US) 1985-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165411-A1 Sterically hindered phosphine ligands and uses thereof NRP1, NR2C2, CXCR1 TSHR 841/4885TDP1 4525/4885ALDH1A1 3092/4885
US-20040133004-A1 Rhodium and iridium complexes RPIA, SIRT5, INPP5B TSHR 2691/4885TDP1 1719/4885ALDH1A1 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.